How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,746 results for

(title:prostate cancer) screening psa

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. (PubMed)

Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. To investigate the efficacy and safety of prostate-specific antigen (PSA) testing to screen for prostate cancer.Systematic review and meta-analysis.Electronic search of Cochrane Central Register of Controlled Trials, Web of Science, Embase, Scopus, OpenGrey, LILACS, and Medline, and search of scientific meeting abstracts and trial registers to April 2018.Randomised controlled trials (...) comparing PSA screening with usual care in men without a diagnosis of prostate cancer.At least two reviewers screened studies, extracted data, and assessed the quality of eligible studies. A parallel guideline committee (BMJ Rapid Recommendation) provided input on the design and interpretation of the systematic review, including selection of outcomes important to patients. We used a random effects model to obtain pooled incidence rate ratios (IRR) and, when feasible, conducted subgroup analyses (defined

Full Text available with Trip Pro

2018 BMJ

2. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening. (PubMed)

PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening. The 2012 United States Preventive Services Task Force recommendation against screening for prostate cancer has impacted rates of prostate-specific antigen (PSA) screening and appears to be associated with declining prostate cancer incidence. Our objective was to characterize health care utilization that may explain these observed (...) trends.MarketScan claims, which capture >30 million privately insured patients in the United States, were queried for all men aged 40-64 years for the years 2008-2014. PSA testing, prostate biopsy, prostate cancer diagnosis, and definitive local treatment were determined using associated International Classification of Diseases, Ninth Revision and Current Procedural Terminology, Fourth Edition codes.There were approximately 6 million qualifying men with a full year of data. PSA testing, prostate biopsy

2018 Cancer

3. Prostate-Specific Antigen (PSA)?based population screening for prostate cancer: an economic analysis

Prostate-Specific Antigen (PSA)?based population screening for prostate cancer: an economic analysis Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an economic analysis Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an economic analysis Tawfik A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Tawfik A. Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an economic analysis. Toronto: Health Quality Ontario (HQO). Ontario Health Technology Assessment Series; 15(11). 2015 Authors' conclusions PSA screening is associated with significant costs to the health care system when the cost of the PSA test itself is considered in addition to the costs of diagnosis, staging, and treatment of screen-detected PCs. Final publication URL Indexing Status

2015 Health Technology Assessment (HTA) Database.

4. Prostate-Specific Antigen (PSA)?based population screening for prostate cancer: an evidence-based analysis

Prostate-Specific Antigen (PSA)?based population screening for prostate cancer: an evidence-based analysis Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an evidence-based analysis Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an evidence-based analysis Pron G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Pron G. Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an evidence-based analysis. Toronto: Health Quality Ontario (HQO). Ontario Health Technology Assessment Series; 15(10). 2015 Authors' conclusions None of the systematic reviews of the randomized controlled screening trials for PC found a statistically significant reduction in relative risk of PC mortality or overall mortality with PSA-based population screening programs

2015 Health Technology Assessment (HTA) Database.

5. Harms of Prostate-Specific Antigen (PSA) screening in prostate cancer: a rapid review

Harms of Prostate-Specific Antigen (PSA) screening in prostate cancer: a rapid review Harms of Prostate-Specific Antigen (PSA) screening in prostate cancer: a rapid review Harms of Prostate-Specific Antigen (PSA) screening in prostate cancer: a rapid review Fergenbaum J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Fergenbaum J. Harms (...) of Prostate-Specific Antigen (PSA) screening in prostate cancer: a rapid review. Toronto: Health Quality Ontario (HQO). Rapid Review. 2015 Authors' conclusions Based on the evidence, the following conclusions can be made: There are major harms (unnecessary risks) associated with PSA screening, including: • harms associated with prostate biopsy • overdiagnosis There are minor harms associated with PSA screening including: • harms associated with PSA testing PSA-based screening for prostate cancer results

2015 Health Technology Assessment (HTA) Database.

6. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. (PubMed)

Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. Prostate cancer screening remains controversial because potential mortality or quality-of-life benefits may be outweighed by harms from overdetection and overtreatment.To evaluate the effect of a single prostate-specific antigen (PSA) screening intervention and standardized diagnostic pathway on prostate cancer-specific mortality.The Cluster Randomized Trial of PSA Testing (...) stage and Gleason grade (range, 2-10; higher scores indicate a poorer prognosis) of prostate cancers identified, all-cause mortality, and an instrumental variable analysis estimating the causal effect of attending the PSA screening clinic.Among 415 357 randomized men (mean [SD] age, 59.0 [5.6] years), 189 386 in the intervention group and 219 439 in the control group were included in the analysis (n = 408 825; 98%). In the intervention group, 75 707 (40%) attended the PSA testing clinic and 67 313

Full Text available with Trip Pro

2018 JAMA

7. Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer. (PubMed)

Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer. More information is needed about effects of prostate-specific antigen (PSA) screening for informed decision making. The objective of our study is to evaluate the effects of an implemented screening decision on the risk of prostate cancer (PC) diagnosis and PC death. In a randomized trial, 31,867 Finnish men (...) aged 55-67 years were allocated to the screening arm and 48,282 to the control arm during 1996-1999. Two to three screening rounds were offered to the screening arm with a PSA cut-off of 4.0 ng/ml. A counterfactual exclusion method was used to adjust for the effects of screening noncompliance and PSA contamination on risk of PC death and PC incidence by prognostic group at 15 years of follow up. After correcting for noncompliance and contamination, PSA screening led to 32.4 (95% CI 26.4, 38.6) more

2019 International journal of cancer

8. Impact of numeracy on understanding of prostate cancer risk reduction in PSA screening. (PubMed)

Impact of numeracy on understanding of prostate cancer risk reduction in PSA screening. Prostate-specific antigen (PSA) screening for prostate cancer in men of average risk remains controversial. Patients' ability to incorporate risk reduction data into their decision-making may depend on their numeracy. We assessed the impact of patients' numeracy on their understanding of the risk reduction benefits of PSA screening. Men attending a general internal medicine clinic were invited to complete (...) , nine, and 36 percent, respectively (P < 0.01). Overall, numeracy was significantly associated with the accuracy of interpreting quantitative benefits of PSA screening. Alternative methods of communicating risk may facilitate shared decision-making in the use of PSA screening for early detection of prostate cancer.

Full Text available with Trip Pro

2017 PLoS ONE

9. Is PSA now “OK”? What the task force really said about the evidence on prostate cancer screening

Is PSA now “OK”? What the task force really said about the evidence on prostate cancer screening Is PSA now "OK"? What the task force really said about the evidence on prostate cancer screening - HealthNewsReview.org Note to our followers: Our nearly 13-year run of daily publication of new content on HealthNewsReview.org came to a close at the end of 2018. Publisher Gary Schwitzer and other contributors may post new articles periodically. But all of the 6,000+ articles we have published contain (...) lessons to help you improve your critical thinking about health care interventions. And those will be still be alive on the site for a couple of years. 6093 Posts Menu April 13, 2017 Is PSA now “OK”? What the task force really said about the evidence on prostate cancer screening Posted By Categories , , , Tags , , Kathlyn Stone is an associate editor with HealthNewsReview.org. You can find her tweets at @KatKStone Reading the headlines on the US Preventive Services Task Force’s (USPSTF) update to its

2017 HealthNewsReview

10. Cohort study: A targeted approach reduces prostate cancer-specific (PSA) screening harms while preserving benefits

Cohort study: A targeted approach reduces prostate cancer-specific (PSA) screening harms while preserving benefits A targeted approach reduces prostate cancer-specific (PSA) screening harms while preserving benefits | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A targeted approach reduces prostate cancer-specific (PSA) screening harms while preserving benefits Article Text Prevention Cohort study A targeted approach reduces prostate

2014 Evidence-Based Medicine (Requires free registration)

11. PSA and Prostate Health Index based prostate cancer screening in a hereditary migration complicated population: implications in precision diagnosis (PubMed)

PSA and Prostate Health Index based prostate cancer screening in a hereditary migration complicated population: implications in precision diagnosis Precision diagnosis requires specific markers for differential ethnic populations. Prostate-Specific Antigen (PSA) level (threshold of 4ng/ml) has been widely used to screen prostate cancer and as reference of pro-biopsy but false diagnosis frequently occurs. Prostate health Index (PHI) is a new diagnosis marker which combines PSA, free PSA (...) on pathological biopsy. In addition, PHI is not correlated to prostate cancer (P=0.4301). Our data suggest that false-positive rate is much higher than the correct-positive diagnosis when using PSA as the first screening. Thus in this cohort study, most patients can not get benefit from the PSA screening for precision PCa diagnosis. As Kazakhstani family trees are unique and complicated because of history and migration, the high rate of over diagnosis might be due to the hyperexpression of PSA via heterosis

Full Text available with Trip Pro

2017 Journal of Cancer

12. Re: Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. (PubMed)

Re: Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. 30227582 2018 09 19 1527-3792 200 4 2018 Oct The Journal of urology J. Urol. Re: Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. 699 S0022-5347(18)43524-0 10.1016/j.juro.2018.07.028 Taneja Samir S SS eng Journal Article 2018 07 17 United States J Urol 0376374 0022-5347 2018 9 20 6 0 2018 9 20 6

2018 The Journal of urology

13. Physician Consultations, Prostate Cancer Knowledge, and PSA Screening of African American Men in the Era of Shared Decision-Making (PubMed)

Physician Consultations, Prostate Cancer Knowledge, and PSA Screening of African American Men in the Era of Shared Decision-Making African American (AA)/Black men are more likely to develop aggressive prostate cancer (PCa), yet less likely to be screened despite guidelines espousing shared decision-making regarding PCa screening and prostate-specific antigen (PSA) testing. Given the documented racial disparities in PCa incidence and mortality, engaging interactions with physicians (...) %) of participants had discussed PCa screening with their physicians. Multivariate analyses were used to assess whether physician-patient conversations predicted PCa knowledge after adjusting for key sociodemographic/economic and health-care variables. Increased PCa knowledge was correlated with younger age, higher income and education, and having discussed the pros and cons of PCa testing with a physician. Serum PSA values were measured by ELISA. Higher-than-normal PSA values were found in 38.5% of men who had

Full Text available with Trip Pro

2018 American journal of men's health

14. Evaluating the Impact of Evidence-based Information About PSA Testing on Prostate Cancer Screening Decisions

Evaluating the Impact of Evidence-based Information About PSA Testing on Prostate Cancer Screening Decisions Evaluating the Impact of Evidence-based Information About PSA Testing on Prostate Cancer Screening Decisions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Evaluating the Impact of Evidence-based Information About PSA Testing on Prostate Cancer Screening Decisions The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03477591 Recruitment Status : Active, not recruiting First Posted : March 26, 2018

2018 Clinical Trials

15. PSA-based screening for prostate cancer: Interpreting the changing guidelines

PSA-based screening for prostate cancer: Interpreting the changing guidelines PSA-based screening for prostate cancer: Interpreting the changing guidelines PSA-based screening for prostate cancer: Interpreting the changing guidelines | | November 8, 2018 3 Shares Comparing the 2018 on prostate cancer screening in the October 15th issue of American Family Physician with its , the first question family physicians ought to ask is: What new evidence compelled the USPSTF to move from recommending (...) against PSA screening in all men to determining that there was a ? Did another major randomized trial show a reduction in all-cause or prostate cancer-specific mortality in men invited to screening? Did other systematic reviewers re-analyze the evidence and find a mortality benefit where ? Have urologists or radiation oncologists developed new treatments for localized prostate cancer that no longer cause erectile dysfunction, urinary incontinence, or infections? No, no, and no. One of the , the only

2018 KevinMD blog

16. Unintended consequences of decreased PSA-based prostate cancer screening. (PubMed)

Unintended consequences of decreased PSA-based prostate cancer screening. In May 2012, the US Preventive Services Task Force issued a grade D recommendation against PSA-based prostate cancer screening. Epidemiologists have concerns that an unintended consequence is a problematic increase in high-risk disease and subsequent prostate cancer-specific mortality.To assess the effect of decreased PSA screening on the presentation of high-risk prostate cancer post-radical prostatectomy (RP). Nine high (...) . The proportion of low-grade GS 3 + 3 cancers decreased significantly (30.2-17.1%) while high-grade GS 8 + cancers increased (8.4-13.5%). There was a 24% increase in absolute numbers of GS 8+ cancers. One-year biochemical recurrence rose from 6.2 to 17.5%. To discern whether increases in high-risk disease were due to referral patterns, propensity score matching was performed. Forest plots of odds ratios adjusted for age and PSA showed significant increases in pathologic stage, grade, and lymph node

2018 World journal of urology

17. Prostate cancer screening

and women who attended one of four "listening sessions" for pretesting PCa educational materials (average age = 55 years). Listening sessions of 1.5-hour duration were conducted to pretest materials; while presenting the materials, researchers 2015 3. Prostate -Specific Antigen?Based Population Screening for Prostate Cancer PSA -Based Population Screening for Prostate Cancer : OHTAC Recommendation. May 2015; pp. 1–5 Prostate -Specific Antigen ( PSA )–Based Population Screening for Prostate Cancer (...) : OHTAC Recommendation HEALTH QUALITY ONTARIO ONTARIO HEALTH TECHNOLOGY ADVISORY COMMITTEE RECOMMENDATION OHTAC recommends against the introduction of a formal, population-based PSA screening program for prostate cancer in Ontario. BACKGROUND Prostate (...) Population Screening for Prostate Cancer : OHTAC Recommendation. May 2015; pp. 1–5 2 average-risk males reduces prostate cancer mortality or overall mortality, increases the detection of prostate cancer , or decreases the rate of aggressive

2018 Trip Latest and Greatest

18. Screening for Prostate Cancer with Prostate-Specific Antigen (PSA) Testing PCO

Screening for Prostate Cancer with Prostate-Specific Antigen (PSA) Testing PCO Screening for Prostate Cancer With Prostate-Specific Antigen Testing: American Society of Clinical Oncology Provisional Clinical Opinion | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2012.43.3441 Journal of Clinical Oncology - published online before print July 16, 2012 PMID (...) An American Society of Clinical Oncology (ASCO) provisional clinical opinion (PCO) offers timely clinical direction to the ASCO membership after publication or presentation of potentially practice-changing data from major studies. This PCO addresses the role of prostate-specific antigen (PSA) testing in the screening of men for prostate cancer. Clinical Context Prostate cancer is the second leading cause of cancer deaths among men in the United States. The rationale for screening men for prostate cancer

Full Text available with Trip Pro

2012 American Society of Clinical Oncology Guidelines

19. PSA TOOL for Prostate Cancer Screening Discussions

PSA TOOL for Prostate Cancer Screening Discussions PSA TOOL for Prostate Cancer Screening Discussions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. PSA TOOL for Prostate Cancer Screening Discussions (...) (PSA) as well as self-reported health status and preferences for treatment. The team now proposes 1) testing this tool first for ease of use in primary care clinics 2) revising this tool based upon feedback from patients and providers, then 3) testing this tool for effectiveness in improving patient knowledge that they have an option to be screened for prostate cancer and of specific factors to be considered in the screening decision. Condition or disease Intervention/treatment Phase Prostate

2017 Clinical Trials

20. Metastatic Prostate Cancer Diagnosed by Bone Marrow Aspiration in an Elderly Man Not Undergoing PSA Screening (PubMed)

Metastatic Prostate Cancer Diagnosed by Bone Marrow Aspiration in an Elderly Man Not Undergoing PSA Screening Prostate cancer screening by PSA testing remains controversial, particularly in the elderly. Practice guidelines from most clinical societies suggest discontinuing PSA screening at age 70 while the USPSTF recommends against screening at any age. Recent reports have demonstrated an increased incidence of metastatic prostate cancer, with men aged 75 or older accounting for roughly half (...) of those newly diagnosed at an incurable stage. We herein describe the case of an elderly gentleman with no history of prostate cancer screening who presented with anorexia and back pain of unclear etiology. Evaluation with bone marrow aspiration revealed a diagnosis of metastatic prostate cancer.

Full Text available with Trip Pro

2017 Urology case reports

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>